Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection
Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recom...
Uložené v:
| Vydané v: | Antimicrobial agents and chemotherapy Ročník 64; číslo 5 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
21.04.2020
|
| Predmet: | |
| ISSN: | 1098-6596, 1098-6596 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its
activity in an aerosol mouse model of
In an aerosol infection BALB/c mouse model using
strain Chester, we treated 58 mice with four combinations of rifampin (RIF) at 10 mg/kg, CFZ at 25 mg/kg, and clarithromycin (CLR) and ethambutol (EMB) at 100 mg/kg. Treatment efficacy was assessed on the basis of lung CFU counts after 2 (M2) and 4 (M4) months of treatment. At M2, CLR-RIF-EMB was slightly but significantly more efficient than CFZ-RIF-EMB (3.02 ± 0.12 versus 3.55 ± 0.28, respectively,
< 0.01), whereas CLR-CFZ-EMB and CLR-CFZ-RIF-EMB dramatically decreased lung CFU counts by 4.32 and 4.47 log
, respectively, compared to untreated group. At M4, CLR-RIF-EMB was significantly more efficient than CFZ-RIF-EMB (2 ± 0.53 versus 2.66 ± 0.22, respectively,
= 0.01). The addition of CLZ to CLR dramatically decreased the lung CFU count, with CFU counts 5.41 and 5.79 log
lower in the CLR-CFZ-EMB and CLR-CFZ-RIF-EMB groups, respectively, than in the untreated group. The addition of CFZ to CLR seems to improve the efficacy of CLR as early as M2 and was confirmed at M4. CFZ, in addition to RIF and EMB, on the other hand, is less effective than CLR-RIF-EMB. These results need to be confirmed by similar studies along with CFZ potential for shortening treatment. |
|---|---|
| AbstractList | Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its
activity in an aerosol mouse model of
In an aerosol infection BALB/c mouse model using
strain Chester, we treated 58 mice with four combinations of rifampin (RIF) at 10 mg/kg, CFZ at 25 mg/kg, and clarithromycin (CLR) and ethambutol (EMB) at 100 mg/kg. Treatment efficacy was assessed on the basis of lung CFU counts after 2 (M2) and 4 (M4) months of treatment. At M2, CLR-RIF-EMB was slightly but significantly more efficient than CFZ-RIF-EMB (3.02 ± 0.12 versus 3.55 ± 0.28, respectively,
< 0.01), whereas CLR-CFZ-EMB and CLR-CFZ-RIF-EMB dramatically decreased lung CFU counts by 4.32 and 4.47 log
, respectively, compared to untreated group. At M4, CLR-RIF-EMB was significantly more efficient than CFZ-RIF-EMB (2 ± 0.53 versus 2.66 ± 0.22, respectively,
= 0.01). The addition of CLZ to CLR dramatically decreased the lung CFU count, with CFU counts 5.41 and 5.79 log
lower in the CLR-CFZ-EMB and CLR-CFZ-RIF-EMB groups, respectively, than in the untreated group. The addition of CFZ to CLR seems to improve the efficacy of CLR as early as M2 and was confirmed at M4. CFZ, in addition to RIF and EMB, on the other hand, is less effective than CLR-RIF-EMB. These results need to be confirmed by similar studies along with CFZ potential for shortening treatment. Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its in vivo activity in an aerosol mouse model of Mycobacterium avium In an aerosol infection BALB/c mouse model using M. avium strain Chester, we treated 58 mice with four combinations of rifampin (RIF) at 10 mg/kg, CFZ at 25 mg/kg, and clarithromycin (CLR) and ethambutol (EMB) at 100 mg/kg. Treatment efficacy was assessed on the basis of lung CFU counts after 2 (M2) and 4 (M4) months of treatment. At M2, CLR-RIF-EMB was slightly but significantly more efficient than CFZ-RIF-EMB (3.02 ± 0.12 versus 3.55 ± 0.28, respectively, P < 0.01), whereas CLR-CFZ-EMB and CLR-CFZ-RIF-EMB dramatically decreased lung CFU counts by 4.32 and 4.47 log10, respectively, compared to untreated group. At M4, CLR-RIF-EMB was significantly more efficient than CFZ-RIF-EMB (2 ± 0.53 versus 2.66 ± 0.22, respectively, P = 0.01). The addition of CLZ to CLR dramatically decreased the lung CFU count, with CFU counts 5.41 and 5.79 log10 lower in the CLR-CFZ-EMB and CLR-CFZ-RIF-EMB groups, respectively, than in the untreated group. The addition of CFZ to CLR seems to improve the efficacy of CLR as early as M2 and was confirmed at M4. CFZ, in addition to RIF and EMB, on the other hand, is less effective than CLR-RIF-EMB. These results need to be confirmed by similar studies along with CFZ potential for shortening treatment.Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its in vivo activity in an aerosol mouse model of Mycobacterium avium In an aerosol infection BALB/c mouse model using M. avium strain Chester, we treated 58 mice with four combinations of rifampin (RIF) at 10 mg/kg, CFZ at 25 mg/kg, and clarithromycin (CLR) and ethambutol (EMB) at 100 mg/kg. Treatment efficacy was assessed on the basis of lung CFU counts after 2 (M2) and 4 (M4) months of treatment. At M2, CLR-RIF-EMB was slightly but significantly more efficient than CFZ-RIF-EMB (3.02 ± 0.12 versus 3.55 ± 0.28, respectively, P < 0.01), whereas CLR-CFZ-EMB and CLR-CFZ-RIF-EMB dramatically decreased lung CFU counts by 4.32 and 4.47 log10, respectively, compared to untreated group. At M4, CLR-RIF-EMB was significantly more efficient than CFZ-RIF-EMB (2 ± 0.53 versus 2.66 ± 0.22, respectively, P = 0.01). The addition of CLZ to CLR dramatically decreased the lung CFU count, with CFU counts 5.41 and 5.79 log10 lower in the CLR-CFZ-EMB and CLR-CFZ-RIF-EMB groups, respectively, than in the untreated group. The addition of CFZ to CLR seems to improve the efficacy of CLR as early as M2 and was confirmed at M4. CFZ, in addition to RIF and EMB, on the other hand, is less effective than CLR-RIF-EMB. These results need to be confirmed by similar studies along with CFZ potential for shortening treatment. |
| Author | Peltier, François Castelain, Sandrine Lanoix, Jean-Philippe Joseph, Cédric Andréjak, Claire |
| Author_xml | – sequence: 1 givenname: Jean-Philippe orcidid: 0000-0003-0463-4636 surname: Lanoix fullname: Lanoix, Jean-Philippe email: lanoix.jean-philippe@chu-amiens.fr organization: Department of Infectious Disease, University Hospital of Amiens-Picardie, Amiens, France – sequence: 2 givenname: Cédric surname: Joseph fullname: Joseph, Cédric organization: Department of Infectious Disease, University Hospital of Amiens-Picardie, Amiens, France – sequence: 3 givenname: François surname: Peltier fullname: Peltier, François organization: AGIR EA 4294, University Center of Research and Health (CURS), Amiens, France – sequence: 4 givenname: Sandrine surname: Castelain fullname: Castelain, Sandrine organization: Department of Microbiology, University Hospital of Amiens-Picardie, Amiens, France – sequence: 5 givenname: Claire surname: Andréjak fullname: Andréjak, Claire organization: Department of Pneumology, University Hospital of Amiens-Picardie, Amiens, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32071046$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUE1LxDAUDKK4H3rzLDl66ZqkH0mPpfixsIsH9VzS5EUjbbKbtgv119vFFYTHvBmYNzxmgc6dd4DQDSUrSpm4L4pyRVic5BHNz9CcklxEWZpn5__4DC267osQMglyiWYxI5ySJJuj_evoIHzYrrcKF6q3B9uP2BtcNt7Ib9taB1g6PWkZbP8ZfDsq6_A00uECgu98g7d-6GBCDc3xdjsqX0vVQ7BDi-XhiGtnYIr37gpdGNl0cH3aS_T--PBWPkebl6d1WWwimaSsj7QixChO6xhopnXCappoEDHhgoMxQjPFU-DC0JjmXGSMEq41rRMqeUKpZkt095u7C34_QNdXre0UNI10ML1bsTgVGWEZ4ZP19mQd6hZ0tQu2lWGs_mpiP5l2a9A |
| CitedBy_id | crossref_primary_10_1128_spectrum_02422_24 crossref_primary_10_1128_aac_01351_24 crossref_primary_10_3390_jcm10194581 crossref_primary_10_1016_j_resinv_2022_05_006 crossref_primary_10_3390_ph18060891 crossref_primary_10_1007_s15010_024_02183_3 crossref_primary_10_3390_antibiotics13060475 crossref_primary_10_1016_j_tube_2024_102503 crossref_primary_10_1128_AAC_02730_20 crossref_primary_10_1128_aac_01853_24 crossref_primary_10_1080_17476348_2025_2479615 crossref_primary_10_3390_vaccines13060619 crossref_primary_10_1016_j_ijantimicag_2023_107061 crossref_primary_10_1186_s12866_023_02831_y crossref_primary_10_3389_fmicb_2025_1539139 crossref_primary_10_1183_23120541_00642_2021 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 American Society for Microbiology. |
| Copyright_xml | – notice: Copyright © 2020 American Society for Microbiology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1128/AAC.02349-19 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1098-6596 |
| ExternalDocumentID | 32071046 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 0R~ 23M 2WC 39C 4.4 53G 5GY 5RE 5VS 6J9 AAGFI ACGFO ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CS3 CUY CVF DIK E3Z EBS ECM EIF F5P FRP GX1 H13 HH5 HYE HZ~ H~9 K-O KQ8 L7B LSO NPM O9- OK1 P2P RHI RNS RPM RSF TR2 UHB W2D W8F WH7 WOQ X7M 7X8 |
| ID | FETCH-LOGICAL-a452t-dc00fc71b3e16dd42b14de830787eff8d2c75e78f13197862107dd1b41a7411d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000528256200057&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1098-6596 |
| IngestDate | Thu Sep 04 19:02:50 EDT 2025 Mon Jul 21 06:02:40 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Mycobacterium avium treatment clofazimine mouse model |
| Language | English |
| License | Copyright © 2020 American Society for Microbiology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a452t-dc00fc71b3e16dd42b14de830787eff8d2c75e78f13197862107dd1b41a7411d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-0463-4636 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/7179583 |
| PMID | 32071046 |
| PQID | 2358602607 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2358602607 pubmed_primary_32071046 |
| PublicationCentury | 2000 |
| PublicationDate | 20200421 |
| PublicationDateYYYYMMDD | 2020-04-21 |
| PublicationDate_xml | – month: 4 year: 2020 text: 20200421 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2020 |
| SSID | ssj0006590 |
| Score | 2.4242673 |
| Snippet | Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| SubjectTerms | Aerosols Animals Antitubercular Agents - administration & dosage Antitubercular Agents - therapeutic use Clarithromycin - administration & dosage Clarithromycin - therapeutic use Clofazimine - pharmacology Clofazimine - therapeutic use Colony Count, Microbial Drug Synergism Ethambutol - therapeutic use Female Lung - microbiology Mice Mice, Inbred BALB C Microbial Sensitivity Tests Mycobacterium avium - drug effects Mycobacterium avium-intracellulare Infection - drug therapy Mycobacterium avium-intracellulare Infection - microbiology Rifampin - therapeutic use Treatment Outcome |
| Title | Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32071046 https://www.proquest.com/docview/2358602607 |
| Volume | 64 |
| WOSCitedRecordID | wos000528256200057&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB_8PO5FvT31_CQHh09GmzZt0ycpi6LgLgsq7NuSJhMQ1lZvVah_vZO2y74dB0IJfQn9yGQ-MjO_H8AfhVJiEQecNJ_kEjPLlRWKZDlCZ50whWsahW_T4VCNx9moO3CbdWWVc53YKGpbGX9Gfu5bOj1dUpBePL9wzxrls6sdhcYyrEbkynipTscLtPAkzlo0gkxxuk_mhe-hOs_z_hmZK5lx8Q_nsjEyV5tffb0t2OjcS5a38vADlrDswXpLOFn34NugS6X34GTUglbXp-x-0YM1O2UnbLSAs65_wstd7fsDG0BnlpuWbYJVjvWnldMfnhUMmS4t86U-j5524ammRzC6dMlyJDNcTdmgepsh88xrUz93UBtSJA1Q9NsT0-9-vOnqwspteLi6vO9f846ogWsZh6_cmiBwJhVFhCKxVoaFkBYVqQ-VonPKhiaNMVVO0IZPKYaimNNaUUihyaERNtyBlbIq8RcwkRQYWa3iABNprNOZCrS0ujCBIWcm2YPf8_8_oY3gsxu6RPqEyWIF9mC3XcTJc4vYMYlC70nJZP8_Zh_A99DH1IHkoTiEVUdqAI9gzby_Ps7-HjcSRuNwNPgE0KHc7A |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synergistic+Activity+of+Clofazimine+and+Clarithromycin+in+an+Aerosol+Mouse+Model+of+Mycobacterium+avium+Infection&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Lanoix%2C+Jean-Philippe&rft.au=Joseph%2C+C%C3%A9dric&rft.au=Peltier%2C+Fran%C3%A7ois&rft.au=Castelain%2C+Sandrine&rft.date=2020-04-21&rft.eissn=1098-6596&rft.volume=64&rft.issue=5&rft_id=info:doi/10.1128%2FAAC.02349-19&rft_id=info%3Apmid%2F32071046&rft_id=info%3Apmid%2F32071046&rft.externalDocID=32071046 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-6596&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-6596&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-6596&client=summon |